Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P10997
UPID:
IAPP_HUMAN
Alternative names:
Amylin; Diabetes-associated peptide; Insulinoma amyloid peptide
Alternative UPACC:
P10997; Q0ZD87; Q14598
Background:
Islet amyloid polypeptide, also known as Amylin, plays a crucial role in glucose metabolism. It selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle tissues, distinguishing its function from adipocyte glucose metabolism. This protein, identified by the accession number P10997, is also referred to as Diabetes-associated peptide and Insulinoma amyloid peptide.
Therapeutic significance:
Understanding the role of Islet amyloid polypeptide could open doors to potential therapeutic strategies. Its unique ability to regulate glucose metabolism in muscle tissues without affecting adipocytes highlights its significance in metabolic research and potential drug discovery.